{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:25Z","timestamp":1790946145648,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.exphem.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T20:20:50Z","timestamp":1671222050000},"page":"40-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5662-9743","authenticated-orcid":false,"given":"Yutthana","family":"Rittavee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-8634","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Artus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Desterke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora","family":"Simanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-7509","authenticated-orcid":false,"given":"Lucas Eduardo Botelho","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Riccaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Coignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8134-079X","authenticated-orcid":false,"given":"Yousef","family":"Ijjeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Hugues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Bennaceur-Griscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-0137","authenticated-orcid":false,"given":"Ali G.","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adlen","family":"Foudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.12.003_bib0001","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.exphem.2022.12.003_bib0002","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2022.12.003_bib0003","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.12.003_bib0004","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.12.003_bib0005","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.12.003_bib0006","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.12.003_bib0007","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood-2011-12-396226","article-title":"BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia","volume":"119","author":"Chomel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.12.003_bib0008","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.12.003_bib0009","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.12.003_bib0010","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.12.003_bib0011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.12.003_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.12.003_bib0013","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2022.12.003_bib0014","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.12.003_bib0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.12.003_bib0016","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.12.003_bib0017","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/aapsj070101","article-title":"Characterization of the human MDR1 gene","volume":"7","author":"Bodor","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.exphem.2022.12.003_bib0018","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.12.003_bib0019","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2022.12.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120437","article-title":"The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance","volume":"296","author":"Navabi","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.exphem.2022.12.003_bib0021","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428194.2016.1243676","article-title":"miRNAs in chronic myeloid leukemia: small molecules, essential function","volume":"58","author":"Litwi\u0144ska","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2022.12.003_bib0022","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2022.12.003_bib0023","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3892\/ol.2017.5727","article-title":"Expression, regulation and function of miR-495 in healthy and tumor tissues","volume":"13","author":"Chen","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.exphem.2022.12.003_bib0024","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/jcmm.13114","article-title":"miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression","volume":"21","author":"Zou","year":"2017","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.exphem.2022.12.003_bib0025","doi-asserted-by":"crossref","first-page":"e82062","DOI":"10.1371\/journal.pone.0082062","article-title":"Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance","volume":"8","author":"Xu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.exphem.2022.12.003_bib0026","first-page":"341","article-title":"Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival","volume":"51","author":"Komatsu","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.12.003_bib0027","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","article-title":"Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis","volume":"1","author":"Kubonishi","year":"1983","journal-title":"Int J Cell Cloning"},{"key":"10.1016\/j.exphem.2022.12.003_bib0028","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/sj.leu.2401730","article-title":"Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7","volume":"14","author":"Issaad","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.12.003_bib0029","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bbrc.2018.07.127","article-title":"Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy","volume":"503","author":"Sandt","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2022.12.003_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.18632\/oncoscience.9","article-title":"Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors","volume":"1","author":"Aggoune","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.exphem.2022.12.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115293","article-title":"Universal stem-loop primer method for screening and quantification of microRNA","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2022.12.003_bib0032","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2022.12.003_bib0033","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.exphem.2022.12.003_bib0034","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Network","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.12.003_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13059-019-1629-z","article-title":"Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data","volume":"20","author":"Liu","year":"2019","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2022.12.003_bib0036","doi-asserted-by":"crossref","first-page":"eaav1741","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.12.003_bib0037","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2022.12.003_bib0038","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nprot.2015.052","article-title":"NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data","volume":"10","author":"Xia","year":"2015","journal-title":"Nat Protoc"},{"key":"10.1016\/j.exphem.2022.12.003_bib0039","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene Ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"issue":"Web Server issue","key":"10.1016\/j.exphem.2022.12.003_bib0040","doi-asserted-by":"crossref","first-page":"W169","DOI":"10.1093\/nar\/gkt393","article-title":"DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows","volume":"41","author":"Paraskevopoulou","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2022.12.003_bib0041","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.3390\/ijms21114057","article-title":"Embryonic program activated during blast crisis of chronic myelogenous leukemia (CML) implicates a TCF7L2 and MYC cooperative chromatin binding","volume":"21","author":"Desterke","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2022.12.003_bib0042","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.cellsig.2009.07.013","article-title":"Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells","volume":"21","author":"Fukumoto","year":"2009","journal-title":"Cell Signal"},{"key":"10.1016\/j.exphem.2022.12.003_bib0043","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.bbrc.2017.12.135","article-title":"Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels","volume":"495","author":"Miyashita","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2022.12.003_bib0044","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4161\/epi.4.3.8752","article-title":"Epigenetic analysis of childhood acute lymphoblastic leukemia","volume":"4","author":"Dunwell","year":"2009","journal-title":"Epigenetics"},{"key":"10.1016\/j.exphem.2022.12.003_bib0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/pgs-2018-0169","article-title":"Identification of a single-nucleotide polymorphism within CDH2 gene associated with bone morbidity in childhood acute lymphoblastic leukemia survivors","volume":"20","author":"Aaron","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.exphem.2022.12.003_bib0046","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbrc.2014.11.083","article-title":"Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3","volume":"456","author":"Li","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2022.12.003_bib0047","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/onc.2010.618","article-title":"miR-495 is upregulated by E12\/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1","volume":"30","author":"Hwang-Verslues","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2022.12.003_bib0048","doi-asserted-by":"crossref","first-page":"19397","DOI":"10.1073\/pnas.1217519109","article-title":"miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia","volume":"109","author":"Jiang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2022.12.003_bib0049","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/jcp.24876","article-title":"A miRNA Signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes","volume":"230","author":"Cattaneo","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.exphem.2022.12.003_bib0050","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3892\/ol.2020.11748","article-title":"Clinical significance of miR-372 and miR-495 in acute myeloid leukemia","volume":"20","author":"Zhang","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.exphem.2022.12.003_bib0051","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1477-7819-11-87","article-title":"microRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6","volume":"11","author":"Chen","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.exphem.2022.12.003_bib0052","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2015.35","article-title":"Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells","volume":"29","author":"Lu","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.12.003_bib0053","doi-asserted-by":"crossref","first-page":"29559","DOI":"10.1038\/srep29559","article-title":"Impact of ABCB1 1236C\u2009>\u2009T-2677G\u2009>\u2009T-3435C\u2009>\u2009T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib","volume":"6","author":"Dessilly","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2022.12.003_bib0054","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/jcb.24665","article-title":"miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A)","volume":"115","author":"Song","year":"2014","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.exphem.2022.12.003_bib0055","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1002\/jcp.29266","article-title":"Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495\/NRF2","volume":"235","author":"Li","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.exphem.2022.12.003_bib0056","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bbrc.2017.03.044","article-title":"TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495","volume":"486","author":"Ye","year":"2017","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22008384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22008384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:38:15Z","timestamp":1759567095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22008384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":56,"alternative-id":["S0301472X22008384"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.12.003","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.10.17.512501","asserted-by":"object"}]},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}